Nearly every clinical specialty in medicine has a corresponding pharmacist organization behind it: oncology, infectious disease, psychiatry, critical care. Dermatology doesn't. That gap isn't cosmetic. It shows up as real patients getting worse guidance than they should, and real pharmacists doing dermatology-adjacent work every day without the specialty infrastructure — training, standards, community — that every other complex therapeutic area takes for granted. This is the full argument for why that needs to change, and why the change is already underway elsewhere.

1. The Access Gap

Dermatologic disease is common, and dermatologic expertise is scarce. National surveys of physician appointment wait times put the average wait for a new dermatology appointment at 34.5 days — a figure that has climbed steadily and runs considerably longer in regions with lower dermatologist density. In areas with fewer than one dermatologist per 100,000 people, median wait times for urgent concerns have been measured as high as 13.6 weeks. Nationally, dermatologist density still falls short of the benchmark of 3.77 per 100,000 people generally considered adequate, even after modest workforce growth in recent years.

At the same time, the multibillion-dollar OTC skincare and cosmetic industry operates with almost no clinical oversight. Patients are left to sort evidence from marketing largely on their own, in a space where misinformation is cheap to produce and expensive to correct.

2. Why Pharmacists

Pharmacists are already positioned to close that gap, whether or not the profession has formally recognized it. They are the most accessible licensed healthcare professionals in the country: a nationwide geographic analysis found that 88.9% of the U.S. population lives within five miles of a community pharmacy, a figure that holds up even in many rural areas that have lost other forms of local healthcare access entirely.

That accessibility means pharmacists are already fielding dermatologic questions constantly — which acne product to try, whether a rash needs a doctor, which sunscreen is actually broad-spectrum — almost always without any dermatology-specific training standing behind the answer. The demand for that expertise already exists at the pharmacy counter. What's missing is the infrastructure to make sure the answer is a good one.

3. The Full-Spectrum, Biologics Reality

Dermatologic therapy today spans a genuinely enormous range: OTC retinoids and sunscreens on one end, complex biologics — IL-17, IL-23, and TNF-alpha inhibitors for conditions like psoriasis and hidradenitis suppurativa — on the other, with prior authorization, self-injection training, and adverse-effect monitoring in between. Pharmacists already do this work. Community pharmacists field the OTC end of that spectrum daily. Specialty pharmacists manage the biologic end: benefits investigation, prior authorization, injection technique counseling, and long-term adherence and safety monitoring for exactly the drug classes reshaping how the specialty treats moderate-to-severe disease.

No other part of pharmacy practice already spans that particular range — OTC counseling through biologic specialty management, in the same therapeutic area — without a dedicated professional home behind the people doing it. That's the case for dermatology pharmacy as its own specialty: not a new role, but formal recognition and infrastructure for work pharmacists are already doing.

4. The Regulatory Trajectory

None of this requires inventing a new model. Versions of it already exist. In January and October 2023, Ontario's pharmacy regulator authorized pharmacists to independently prescribe for an expanded list of minor ailments that explicitly includes acne, dermatitis, diaper dermatitis, and impetigo — skin conditions, prescribed by pharmacists, under a formal provincial framework. Idaho has operated under a broad independent-prescribing law since 2019 that lets pharmacists prescribe for minor, self-limiting conditions using professional judgment rather than a fixed drug list, a framework pharmacies in the state already apply to conditions like acne and cold sores. And in 2024, Tennessee became the latest in a growing list of states to expand pharmacists' independent prescriptive authority, part of a broader national trend toward giving pharmacists more formal clinical authority, even where that particular law wasn't dermatology-specific.

Taken together, these aren't isolated policy experiments. They're the leading edge of a direction the entire profession is already moving in. Dermatology pharmacy doesn't need to make the case that pharmacists can take on more clinical authority in this space from scratch — it needs the professional infrastructure, standards, and community to catch up to a trend that's already underway.

The Bottom Line

The gap is documented. The accessibility argument is documented. The full-spectrum clinical work is already happening inside pharmacy practice. And the regulatory precedent for a larger pharmacist role in skin health already exists in more than one place. What doesn't exist yet, in most of the country, is the specialty infrastructure to organize any of it: training standards, a professional community, and a body making the case at the level nearly every other clinical specialty in pharmacy already has. That's what the Society of Dermatology Pharmacists exists to build.

This piece reflects the Society's view of the case for dermatology pharmacy as a specialty, built on the sources cited below. It is not a statement of current scope of practice in any jurisdiction; pharmacists should confirm their own state or provincial regulations before acting on any prescriptive authority referenced here.

Sources